Practical Synthesis of N-Anilinylphenothiazines Using a Cyclic Hypervalent Iodine Coupling Reagent

Kana Yanase; Koji Morimoto; Toshifumi Dohi; Yasuyuki Kita

doi:10.1055/a-2383-0958

Synthesis, Inhaltsverzeichnis

Synthesis 2025; 57(04): 748-753
DOI: 10.1055/a-2383-0958

psp

Practical Synthesis of N-Anilinylphenothiazines Using a Cyclic Hypervalent Iodine Coupling Reagent

Kana Yanase

^aCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu Shiga, 525-8577, Japan

,

Koji Morimoto ∗

^aCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu Shiga, 525-8577, Japan

^bResearch Organization of Science and Technology, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan

,

Toshifumi Dohi

^aCollege of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu Shiga, 525-8577, Japan

^bResearch Organization of Science and Technology, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan

,

Yasuyuki Kita ∗

^bResearch Organization of Science and Technology, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan

› Institutsangaben

Abstract

Alle Artikel dieser Rubrik

Abstract

An improved protocol for the synthesis of N-anilinylphenothiazines based on the coupling reaction of anilines with phenothiazines using cyclic iodine(III) reagent is presented. In the improved method, the product can be isolated and purified without using column chromatography, and the cyclic hypervalent iodine reagent can be quantitatively recovered by aliquot manipulation. The workup procedure presented here is simpler compared to previously reported ones, facilitating large-scale synthesis. The para-selective phenothiazination of nitrogen-containing heterocycles such as hydroquinoline, which is important in pharmacology, was also successfully performed.

Key words

hypervalent iodine(III) reagent - aryl C–H amination - solid–liquid separation - coupling reaction - N-anilinylphenothiazines

Volltext

Referenzen

References
1 Mitchell S. Curr. Drug Targets 2006; 7: 1181
2 Ohlow MJ, Moosmann B. Drug Discov. Today 2011; 16: 119
3 Romero NA, Nicewicz DA. Chem. Rev. 2016; 116: 10075
4 Jiang K, Han S, Ma M, Zhang L, Zhao Y, Chen M. J. Am. Chem. Soc. 2020; 142: 7108
5 Sun C.-L, Shi Z.-J. Chem. Rev. 2014; 114: 9219
6 Louillat ML, Patureau FW. Chem. Soc. Rev. 2014; 43: 901
7 Patureau FW. ChemCatChem 2019; 11: 5227
8 Kita Y, Dohi T. Chem. Rec. 2015; 15: 886
9 Dohi T, Kita Y. Chem. Commun. 2009; 16: 2073
10 Kita Y, Tohma H, Inagaki M, Hatanaka K, Yakura T. Tetrahedron Lett. 1991; 32, 4321
11 Kita Y, Tohma H, Hatanaka K, Takada T, Fujita S, Mitoh S, Sakurai H, Oka S. J. Am. Chem. Soc. 1994; 116: 3684
12 Morimoto K, Yanase K, Toda K, Takeuchi H, Dohi T, Kita Y. Org. Lett. 2022; 24: 6088
13 Anastas P, Eghbali N. Chem. Soc. Rev. 2010; 39: 301
14 Erythropel HC, Zimmerman JB, De Winter TM, Petitjean L, Melnikov F, Lam CH, Lounsbury AW, Mellor KE, Janković NZ, Tu Q, Pincus LN, Falinski MM, Shi W, Coish P, Plata DL, Anastas PT. Green Chem. 2018; 20: 1929
15 Vaškevičius M, Kapočiūtė-Dzikienė J, Šlepikas L. Electronics 2022; 11: 1360
16 Iinuma M, Moriyama K, Togo H. Eur. J. Org. Chem. 2014; 772
17 Manivannan E, Prasanna S. Bioorganic Med. Chem. Lett. 2005; 15: 4496
18 Bradner WT. Cancer Treat. Rev. 2001; 27: 35
19 Nagata N, Miyakawa M, Amano S, Furuya K, Yamamoto N, Nejishima H, Inoguchi K. Bioorganic Med. Chem. Lett. 2011; 21: 6310
20 Vemuri PY, Wang Y, Patureau FW. Org. Lett. 2019; 21: 9856
21 Wu YC, Jiang SS, Song RJ, Li JH. Chem. Commun. 2019; 55: 4371

Zusatzmaterial

Supporting Information